Replies to post #8179 on GT Biopharma Inc (GTBP)

[simon wagstaff]

Too bad that OXS-1550 is a bi-specific antibody and not really an immunotherapy.

"Now, as yet, there’s no proof that the TrIKE tech can combine with OXS-1550 (this is speculative on our part) but that the company is working with UoM on the technology suggests that this is their end-goal. "